-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with early-stage relapsed or refractory large B-cell lymphoma receiving first-line chemoimmunotherapy have a poor prognosis
.
In a recent study published in the top medical journal N Engl J Med, researchers conducted an international Phase 3 trial
.
Subjects were randomized 1:1 to receive either Axicabtagene ciloleucel (axi-cel, an autologous anti-CD19 chimeric antigen receptor T-cell therapy) or standard of care (investigator-selected and prescribed chemoimmunotherapy for two or three cycles followed by high-dose chemotherapy and autologous stem cell transplantation (chemoimmunotherapy) in responding patients)
stem cell
The study's primary endpoint was event-free survival, and the study's key secondary endpoints were treatment response and overall survival
.
The researchers also assessed the safety of the treatment
A total of 180 patients were randomly assigned to receive axi-cel and 179 to standard care
.
Analysis of the primary endpoint of event-free survival showed that axi-cel treatment was superior to standard care
CONCLUSIONS: Axi- cel treatment significantly improved event-free survival and treatment response in patients with early-stage relapsed or refractory large B-cell lymphoma compared with standard therapy, but with the expected high levels of toxicity
.
.
Original Credit:
Frederick L.
Locke, et al.
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma .
